中文

东宝生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-24
ItemAmountY/Y
Revenue¥0.19B+1.3%
Gross profit¥0.05B
Operating income¥0.02B
Net income¥0.02B+3.4%
Gross margin24.3%Net margin 10.3%
Revenue Q/Q-10.3%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.14B75.7%
R&D¥0.01B2.8%
SG&A¥0.02B8.3%
Tax & other¥0.00B1.5%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

飞力达瑞丰光电佳云科技瑞丰高材迪安诊断ST天玑宝莱特融捷健康新开普依米康初灵信息金信诺

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies